Zaderej Karen L.

Director Karen L. Zaderej purchased 10,000 shares at blended average $5.90 across two transactions, raising holdings 37.7% to 36.5K shares

Karen L. Zaderej, a Director at EyePoint Pharmaceuticals, completed 2 purchases totaling 10,000 shares for $59,000.00 at an average price of $5.90 on 2025-05-16 and 2025-05-19, expanding her position by 37.7% from 26,500 to 36.5K shares. The current price of $6.10 is 52.9% below the 52-week high of $12.94, positioning these purchases near recent lows in a stock that has declined 6.7% over 90 days. Zaderej's cross-ticker track record shows a 100.00% 90-day win rate with average 90-day returns of +14.9% across 3 prior open-market buys; her prior purchase at EYPT on 2024-08-19 also achieved a +14.9% 90-day return, demonstrating consistent timing execution at this ticker specifically. The company is unprofitable with a net income of $-45.2M on quarterly revenue of $24.5M, yet the director's continued accumulation at reduced prices after a 52-week decline suggests conviction despite current fundamentals.

Director Karen L. Zaderej bought 10,000 shares at blended avg $5.44 across 2 purchases; holds now 26.5K shares, +60.6% vs pre-transaction.

Director Karen L. Zaderej purchased a total of 10,000 shares (10.0K shares) for $54,450.00 across 2 separate transactions on May 14-15, 2025, at prices of $5.42 and $5.47, increasing her holdings by 60.6% from 16,500 to 26.5K shares. The company operates at a significant loss—net income of $-45,195,000.00 for the latest full fiscal year—while posting quarterly revenue of $24,453,000.00 with annual revenue growth at -6.0%, indicating operational headwinds. Her prior buy at this ticker on 2024-08-19 delivered positive returns at both 30-day (+11.6%) and 90-day (+14.9%) intervals, and her cross-ticker track record shows 1 prior buy with a 100.00% 90-day win rate, though the sample remains modest. The current stock price of $5.72 sits at -55.8% from the 52-week high of $12.94, creating a depressed valuation environment where the director elected to substantially increase her stake.

Director Zaderej buys 12,500 shares at $7.98 as EYPT stock down -69.5% from 52-week high; cluster of 4 insider buys in 14 days

Director Karen L. Zaderej purchased 12,500 shares at $7.98 on 2024-08-19, tripling her position from 4,000 to 16,500 shares (+312.5% increase). The transaction occurred when the stock was trading 69.5% below its 52-week high of $29.71. Notably, 3 other insiders bought within the same 14-day window, forming a cluster buy pattern. Against this backdrop, the company is unprofitable (net income $-30.8M) despite recent revenue growth of 11.1%, with the most recent quarterly revenue at $9.5M. This synchronized insider purchasing at a significant discount from recent highs, combined with the company's cash burn despite top-line growth, presents a pattern investors should examine carefully given the disconnect between growth narrative and profitability.